Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

FINAL TERMS/UPSIZE: Biogroup E800m sr sec at 3.375%; E250m unsec at 5%

HYC European Market: Deal Flow - General

Biogroup EUR1.05bn (up from EUR1bn) 144A/Reg S 2-part. Via JPM (B&D)/BNP/Natixis joint glocos/Citi/CA/DB/GS/HSBC joint books. List Lux. NY law. New term loan size reduced by EUR50m to EUR1.45bn.

- CAB EUR800m (up from EUR750m) sr sec notes due 2028 (7y). NC3 (50%,25%,par). Equity claw: 3y 40%. B2/B-/B+ (negative/stable/stable). Special call: 10% per year the 1st 3 years at 103. IPT mid to high 3s. Px talk: 3.25%-3.50%. Final terms: EUR800m at 3.375%.

- Laboratoire Eimer EUR250m sr notes due 2029 (8y). NC3 (50%,25%,par). Equity claw: 3y 40%. Caa1/CCC/CCC+ (negative/stable/stable). IPT mid 5s. Px talk: 5.00%-5.25%. Final terms: EUR250m at 5.00%.

Did investor call at 10am UKT 01/25. Virtual meetings available through yesterday. Books closed at 10am UKT today. Pricing today. UOP: along with a new EUR1.45bn (down from EUR1.5bn) term loan and EUR80m cash on hand, to repay its existing EUR2.015bn term loan, existing EUR305m 2nd lien debt and existing EUR219m PIK notes. Biz: Leading private medical laboratory testing business in France and Belgium.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.